title: Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
abstract: The marker CD19 is frequently expressed on the surface of malignant B cells including non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL), which makes it an attractive target for antineoplastic therapy (1). T cells are part of the immune surveillance system for malignant cells (2). Blinatumomab is a bispecific T cell engager (BiTE(®)) antibody that binds both CD3-positive T cells and CD19-positive B cells via its two variable antigen-binding domains. Once bound to both the T and B cell, blinatumomab induces T-cell activation and subsequently perforin-mediated malignant B-cell death. It has shown efficacy in ALL with minimal residual disease, relapsed/refractory ALL, and NHL in phase I and II clinical trials. With a favorable safely profile and promising results, blinatumomab was granted accelerated FDA approval to treat B-cell ALL in December 2014. Herein, we will review the most relevant data related to blinatumomab in ALL.
authors.affiliation: Department of Leukemia, U.T. M.D. Anderson Cancer Center, Houston, Texas, USA.
authors.forename: J
authors.initials: J
authors.lastname: Dahl
authors.affiliation: Department of Leukemia, U.T. M.D. Anderson Cancer Center, Houston, Texas, USA.
authors.forename: M
authors.initials: M
authors.lastname: Mace
authors.affiliation: Department of Leukemia, U.T. M.D. Anderson Cancer Center, Houston, Texas, USA.
authors.forename: H
authors.initials: H
authors.lastname: Kantarjian
authors.affiliation: Department of Leukemia, U.T. M.D. Anderson Cancer Center, Houston, Texas, USA. ejabbour@mdanderson.org.
authors.forename: E
authors.initials: E
authors.lastname: Jabbour
mesh_terms: D000328:Adult; D018033:Antibodies, Bispecific / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018941:Antigens, CD19 / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
chemical_list: D018033:Antibodies, Bispecific; D018941:Antigens, CD19; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; C510808:blinatumomab
keywords: Acute lymphoblastic leukemia; Blinatumomab; Refractory; Relapsed